Skip to search formSkip to main contentSkip to account menu

MN-221

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

bedoradrine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Pharmacokinetics and Pharmacodynamics of MN-221, a Novel, Highly Selective Beta2-Adrenergic Agonist for Treatment of Acute Chronic Obstructive Pulmonary Disease
MN-221 is in development for the treatment of acute exacerbations of COPD and asthma. It is more selective for human β2 receptors… 
2010
2010
Cardiovascular Effects of MN-221 (Bedoradrine) Administered With Albuterol in Dogs
2010
2010
Intravenous MN-221, a Novel, Highly Selective Beta2-Adrenergic Receptor Agonist, Improves Lung Function in Stable Moderate to Severe Chronic Obstructive Pulmonary Disease Patients
2010
2010
Evaluation of MN-221 (Bedoradrine), a Novel, Highly Selective Beta2-Adrenergic Receptor Agonist in Mild to Moderate Asthma via Intravenous Infusion
2010
2010
Comparison of Administration Rates of MN-221 (Bedoradrine), a Novel, Highly Selective Beta2-Receptor Agonist in Patients With Stable Mild to Moderate Asthma
2010
2010
Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling and Simulation Support the Novelty of MN-221, a Highly Selective Beta2-Adrenergic Receptor Agonist for Treatment of Acute Asthma